Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anamorelin - Helsinn Therapeutics/Ono Pharmaceutical

Drug Profile

Anamorelin - Helsinn Therapeutics/Ono Pharmaceutical

Alternative Names: Adlumiz; Anamorelin HCl; Anamorelin hydrochloride; ONO-7643; RC-1291; RC-1291 HCl; ST-1291

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer Helsinn Therapeutics; Ono Pharmaceutical
  • Class Appetite stimulants; Piperidines; Small molecules
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Anorexia; Cachexia
  • Phase II Fatigue

Most Recent Events

  • 25 Feb 2020 Curtin University initiates the phase II ANTHEM trial in Cachexia (associated with malignant mesothelioma) in Australia (PO) (ACTRN12619001324101)
  • 15 Aug 2019 Ono Pharmaceutical completes a phase III trial in Cachexia in Japan (PO) (JapicCTI-163426)
  • 16 Jul 2019 Tufts University and National Institute of Arthritis and Musculoskeletal and Skin Diseases plans a phase I trial for Metabolic bone diseases and Muscular atrophy in the US in August 2019 (NCT04021706)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top